Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2011

View Archived Issues

Long-term safety and efficacy reported from teriflunomide trial TEMSO in relapsing MS

Quadrivalent influenza vaccine is safe and immunogenic in older subjects

First-in-human data on PET tracer BAY-86-9596

Duloxetine may hold promise as therapy for MS-related central neuropathic pain

Novel transient receptor potential TRPV4 channel antagonists prepared by GSK

MediciNova begins phase Ib trial to test repeat dosing of MN-221 in COPD

St. Jude Medical diagnostic technology cleared for use in U.S.

Eviendep may alter neoproliferative processes in intestinal mucosa

Eli Lilly discloses new cannabinoid CB2 receptor agonists

Novel tachykinin NK3 receptor antagonists claimed by Euroscreen

Novel diacylglycerol O-acyltransferase type 1 inhibitors synthesized by AstraZeneca

Palobiofarma prepares novel adenosine A2A receptor antagonists

Amsterdam Molecular Therapeutics announces restructuring

Acceleron Pharma begins phase II trial of ACE-041 in head and neck cancer

New phase Ib/II study of BEZ-235 launched

Pfizer completes acquisition

FDA grants new orphan drug status to BioVaxID

Discussions regarding Biotie's planned acquisition of Newron terminated

Alcon Research begins recruitment in phase I trial of nasal spray solution for allergies

The Medicines Company and Daiichi Sankyo to copromote anticoagulant in Germany

Biogen Idec and Portola enter collaboration for SYK inhibitors

Oxford BioMedica and Mayo Clinic to collaborate on gene therapy for chronic glaucoma

BerGenBio begins preclinical development of lead product

Trophos cardioprotectant enters proof-of-concept phase II trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...